Pilot project allows foreign-invested businesses to boost CGT development
China DailyIn a significant move toward liberalization in the healthcare sector, Shanghai's Pudong New Area witnessed the first batch of six foreign-invested biotechnology companies, including Merck Testing and Frontera Therapeutics, complete changes in their business scopes to include cell and gene therapy last week. The changes signified a milestone in a pilot project that allowed foreign-invested enterprises to engage in the development and application of human stem cells, gene diagnostics and therapeutic technologies in Pudong. The current negative list restricts foreign investment in the development and application of human stem cells and gene diagnostics within the CGT sector, in which China is a world leader. German company Merck Testing said that the updated scope allows the company to localize advanced technologies in Shanghai's Free Trade Zone, engage in cutting-edge biotechnology innovation and better cater to China's biomedical development needs.
History of this topic
Pilot project allows foreign-invested businesses to boost CGT development
China Daily
Pilot project allows foreign-invested businesses to boost CGT development
China Daily
Alliance for stem cell technologies established in Guangzhou[1]- Chinadaily.com.cn
China DailyDiscover Related
